Phase 3 APPLY-PNH Extension Data Show Sustained Benefit of Iptacopan (Fabhalta) for PNH

Results showed treatment with iptacopan through 48 weeks caused hemoglobin-level increases, blood transfusion avoidance, and reductions in patient-reported fatigue.

Related Keywords

Italy ,California ,United States ,San Diego ,American ,Antonio Risitano ,Iptacopan Fabhalta ,Giuseppe Moscati ,Reference Center ,European School Of Haematology Antonio Risitano ,Novartis ,American Society Of Hematology ,Interest Group ,Drug Administration ,European School ,Hematopoietic Transplant Unit ,Aplastic Anemia ,Paroxysmal Nocturnal Hemoglobinuria ,Annual Meeting ,Paroxysmal Nocturnal ,Iptacopan ,Fabhalta ,Apply Pnh ,Phase 3 ,Pnh ,Hemoglobin ,Blood Transfusion ,Fatigue ,